Boston Scientific (NYSE:BSX) Hits New 12-Month Low – What’s Next?

Shares of Boston Scientific Corporation (NYSE:BSX) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $61.09 and last traded at $60.9870, with a volume of 3119408 shares. The stock had previously closed at $62.59.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Leerink reiterates Outperform after CHAMPION‑AF met primary safety and efficacy endpoints; analyst notes nuances but kept a bullish stance. Leerink Reiterates Outperform on Boston Scientific (BSX) After CHAMPION-AF Readout
• Positive Sentiment: Boston Scientific closed the buyout of Valencia Technologies, strengthening its competitive position vs. Medtronic in an under‑penetrated market. Boston Scientific closes buyout of Valencia Technologies
• Neutral Sentiment: Article highlights BSX as a Wall Street favorite with ambitious price targets — useful for long‑term perspective but not immediate catalyst. 3 of Wall Street’s Favorite Stocks for Long-Term Investors
• Negative Sentiment: Gross Law Firm issued a shareholder alert encouraging investors to seek lead‑plaintiff status in a securities lawsuit covering the class period. BSX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action
• Negative Sentiment: Bernstein Liebhard announces a securities‑fraud class action filed against BSX for purchases between July 23, 2025 and Feb 3, 2026. SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Boston Scientific Corporation (BSX)
• Negative Sentiment: Rosen Law Firm and related outlets are urging investors to secure counsel ahead of a May 4, 2026 lead‑plaintiff deadline — another driver of headline risk. ROSEN, LEADING TRIAL ATTORNEYS, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline
• Negative Sentiment: Levi & Korsinsky and Glancy Prongay Wolke & Rotter issued alerts alleging concealment of electrophysiology demand weaknesses and reminding investors of the May 4 deadline. BSX Investor Alert: Securities Fraud Lawsuit — Alleged Concealment of Electrophysiology Demand Weaknesses
• Negative Sentiment: Faruqi & Faruqi and other firms continue outreach on the same class period, keeping legal risk and headline frequency elevated. BSX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Argus raised shares of Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Monday, March 16th. TD Cowen lowered their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. The Goldman Sachs Group lowered their price target on shares of Boston Scientific from $98.00 to $93.00 and set a “buy” rating on the stock in a report on Friday, March 27th. Finally, Evercore lowered their price target on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $104.36.

Boston Scientific Stock Down 2.0%

The company has a market cap of $91.14 billion, a P/E ratio of 31.61, a price-to-earnings-growth ratio of 0.97 and a beta of 0.78. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The firm’s 50 day moving average price is $73.99 and its 200-day moving average price is $89.01.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.50% of the stock is owned by corporate insiders.

Institutional Trading of Boston Scientific

Hedge funds have recently modified their holdings of the company. Steph & Co. acquired a new stake in Boston Scientific during the 3rd quarter worth approximately $25,000. Financial Consulate Inc. acquired a new stake in Boston Scientific during the 3rd quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp raised its holdings in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the period. FWL Investment Management LLC acquired a new stake in Boston Scientific during the 2nd quarter worth approximately $26,000. Finally, Swiss RE Ltd. acquired a new stake in Boston Scientific during the 4th quarter worth approximately $26,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.